• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Jim Shrine

Articles by Jim Shrine

Sepracor, GSK Enter $155M Deal Covering Global Lunesta Rights

Sep. 12, 2007
By Jim Shrine
Sepracor Inc. entered a potential $155 million deal with GlaxoSmithKline plc covering its insomnia product Lunesta in Europe and elsewhere, about six weeks after it filed for European approval of the drug. (BioWorld Today)
Read More

Sepracor, GSK Enter $155M Deal Covering Global Lunesta Rights

Sep. 12, 2007
By Jim Shrine
Sepracor Inc. entered a potential $155 million deal with GlaxoSmithKline plc covering its insomnia product Lunesta in Europe and elsewhere, about six weeks after it filed for European approval of the drug. (BioWorld Today)
Read More

Ablynx, BI Enter Potential $1.8B Deal For 10 Nanobody Targets

Sep. 10, 2007
By Jim Shrine
Ablynx NV signed its third headline-grabbing deal in 10 months and fifth significant alliance overall, a potential €1.3 billion collaboration that likely will be the last of its kind as the company plans to further assert the strong position of its Nanobody platform going forward. (BioWorld Today)
Read More

Ablynx, BI Enter Potential $1.8B Deal For 10 Nanobody Targets

Sep. 10, 2007
By Jim Shrine
Ablynx NV signed its third headline-grabbing deal in 10 months and fifth significant alliance overall, a potential €1.3 billion collaboration that likely will be the last of its kind as the company plans to further assert the strong position of its Nanobody platform going forward. (BioWorld Today)
Read More

NeurogesX Reports Positive Phase III Study Of NGX-4010

Sep. 5, 2007
By Jim Shrine
NeurogesX Inc. reported the pain patch NGX-4010 met primary and secondary endpoints in a third Phase III trial, and the second in patients with postherpetic neuralgia. (BioWorld Today)
Read More

NeurogesX Reports Positive Phase III Study Of NGX-4010

Sep. 5, 2007
By Jim Shrine
NeurogesX Inc. reported the pain patch NGX-4010 met primary and secondary endpoints in a third Phase III trial, and the second in patients with postherpetic neuralgia. (BioWorld Today)
Read More

ARYx Seeking $86M In IPO For Work On Large-Market Products

Sep. 4, 2007
By Jim Shrine

ARYx Seeking $86M In IPO For Work On Large-Market Products

Sep. 4, 2007
By Jim Shrine

OncoVista Sells $6.8M Of Units, Acquires Public Shell Company

Aug. 31, 2007
By Jim Shrine

OncoVista Sells $6.8M Of Units, Acquires Public Shell Company

Aug. 31, 2007
By Jim Shrine
Previous 1 2 3 4 5 6 7 8 9 … 25 26 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 25, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 25, 2025.
  • Brain and neural networks

    Proteomics finds surprise commonalities as well as differences in neurodegenerative diseases

    BioWorld
    The switch will be flicked today to make the world’s largest dementia-related proteomics dataset freely available to researchers, at the same time as members of...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 22, 2025
  • Pfizer describes new STAT6 inhibitors

    BioWorld Science
    Pfizer Inc. has identified signal transducer and activator of transcription 6 (STAT6) inhibitors reported to be useful for the treatment of Alzheimer’s disease,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe